|
|
||||||||


*
Department of Dermatology, Kansai Medical University, Moriguchi, Japan;
Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka, Japan; and
Institute for Molecular and Cellular Biology, Osaka University, Osaka, Japan
Xeroderma pigmentosum group A (XPA) gene-deficient
mice easily developed skin cancers by the application of topical
chemical carcinogens as well as by UV irradiation. As certain chemical
carcinogens have been shown to be immunosuppressive, we examined the
inflammatory and immunosuppressive effects of
dimethylbenz(a)anthracene (DMBA) on XPA mice. Compared with
wild-type mice, XPA mice showed greater ear swelling and reduction of
epidermal Langerhans cells after DMBA application. Topical application
of DMBA impaired the induction of contact hypersensitivity, initiated
either locally or at distant sites. These DMBA-induced local and
systemic immunosuppressions were more greatly enhanced in XPA mice than
in wild-type mice. DMBA application induced pronounced production of
PGE2, IL-10, and TNF-
in the skin of XPA mice. Treatment
with indomethacin, a potent inhibitor of PG biosynthesis, inhibited
DMBA-induced inflammation and local immunosuppression. In XPA mice,
increased serum IL-10 was detected after DMBA treatment. Excess
production of PGE2, TNF-
, and IL-10 after DMBA
application may be involved in the enhanced local and systemic
immunosuppression in DMBA-treated XPA mice. Susceptibility to
DMBA-induced skin tumors in XPA mice may be due to easy impairment of
the immune system by DMBA in addition to a defect in the repair of
DMBA-DNA adduct. Enhanced immunosuppression by chemical carcinogens as
well as the mutagenicity of these mutagens might be associated with the
high incidence of internal malignancies seen in XP patients. Moreover,
these results supported the hypothesis that persistent DNA damage is a
trigger for the production of immunoregulatory
cytokines.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |